| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2011-08-23 | KalVista Pharmaceuticals (UK) | £8 million | series A financing round | Novo A/S (Denmark) - SV Life Sciences (UK - USA) | Ophtalmological diseases | Fundraising |
| 2011-08-22 | Autifony Therapeutics (UK) | £10m (€11.4 million) | financing round | Imperial Innovations Group (UK) - SV Life Sciences (UK - USA) | Otorhinolaryngology | Fundraising |
| 2011-08-15 | Evolva (Switzerland) | CHF 30 million (€26.4 million) | private placement | YA Global -Yorkville Advisors LLC (USA) | Technology - Services | Fundraising |
| 2011-08-06 | ugichem (Austria) | €2 million | equity financing round - grant | The BioScience Venture Group (Germany) - Fonds 3 KG - V+ M GmbH & Co (Germany) - Swiss private investors - Austrian Research Promotion Agency (FFG) (Austria) | Autoimmune diseases – Inflammatory diseases | Grant |
| 2011-07-27 | ChronTech Pharma (Sweden) | 25 million SEK (€2.7 million) | private placement | Sunninghill Investments Ltd - Dr. Simon Kukes - Dr. Prem Lachman - the Chairman of the Board, Mr Thomas Lynch | Technology - Services - Infectious diseases | Private placement |
| 2011-07-26 | BioAlliance Pharma (France) | €16.64 million | capital increase | Cancer - Oncology - Rare diseases | Capital increase | |
| 2011-07-25 | Summit (UK) | £1.35 million | private placement | existing and new investors | Rare diseases - Neuromuscular diseases - Infectious diseases | Private placement |
| 2011-07-25 | CEVEC Pharmaceuticals (Germany) | €6 million | financing round | NRW.BANK (Germany) - Creathor Venture Fonds (Germany) - a group of private and institutional investors - ERP Startfonds of KfW bank (Germany) | Technology - Services | Fundraising |
| 2011-07-21 | Pharming (The Netherlands) | €3.2 million | private placement | new US based specialist investors | Rare diseases | Private placement |
| 2011-07-14 | Ark Therapeutics (UK) | €5.3 million | grant | European Commission’s Seventh Framework Program (FP7) | Cardiovascular diseases | Grant |
| 2011-07-14 | Lophius Biosciences (Germany) | €1.4 Million | financing round | All current financial investors of the company | Translantation - Infectious diseases | Fundraising |
| 2011-07-06 | Antisense Pharma - now Isarna Therapeutics (Germany) | € 8 million | capital increase | MIG Funds 2, 3 and 9 GAF |
Cancer - Oncology - Ophtalmological diseases - Fibrotic diseases | Capital increase |
| 2011-07-06 | Vantia Therapeutics (UK) | £4 million (€ 4.55 million) | series B financing round | Novo A/S (Denmark) - SV Life Sciences (UK - USA) - MVM Life Science Partners (UK) | Women health | Fundraising |
| 2011-07-06 | Ark Therapeutics (UK) | €0.6 million | grant | Technology - Services | Grant | |
| 2011-07-01 | Galapagos (Belgium) | capital increase | employees | Technology - Services | Capital increase | |
| 2011-06-29 | Prosonix (UK) | £11.4 million | series B financing round | Ventech (France) - Gilde Healthcare Partners (Netherlands) - Entrepreneurs Fund (UK) - Quest for Growth (Belgium) Solon Ventures (UK) |
Respiratory diseases | Fundraising |
| 2011-06-24 | Neovacs (France) | € 420 000 | capital increase via the issuance independent of preemption rights of 105,500 shares. | The shares were placed with 3 investors. | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases | Capital increase |
| 2011-06-23 | Scil Technology (Germany) | € 0.9 million | grant | Federal Ministry of Education and Research (BMBF)(Germany) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases | Grant |
| 2011-06-21 | Shield Therapeutics (UK) | €8.2m (CHF10m/US$12m) | series A financing round | Inventages Venture Capital | Fundraising | |
| 2011-06-17 | TcLand Expression (France) | € 1.2 million | french and european grants | Oseo (France) - European Regional Development Fund (ERDF) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases | Grant |
